What is TB4-FRAG (Ac-SDKP)?

TB4-FRAG, or Ac-SDKP, is a naturally occurring tetrapeptide derived from thymosin β4. It's an endogenous molecule that plays a significant role in regulating inflammation and fibrosis within the body.

How does TB4-FRAG work in the body?

TB4-FRAG primarily works by inhibiting the signaling pathway of TGF-β1, a key mediator of fibrosis and inflammation. This action helps to reduce collagen production, prevent excessive scar tissue formation, and dampen pro-inflammatory responses, thereby promoting healthier tissue remodeling and repair.

What are the main therapeutic benefits of TB4-FRAG?

Research indicates that TB4-FRAG offers significant anti-fibrotic, anti-inflammatory, and organ-protective benefits. It has shown promise in mitigating fibrosis in organs like the heart, kidneys, and lungs, reducing inflammation in various disease models, and protecting tissues from damage during ischemic events.

Is TB4-FRAG safe for human use?

Currently, TB4-FRAG (Ac-SDKP) is primarily an investigational compound with extensive preclinical data. There are no established human clinical trials or widely recognized therapeutic applications for it as a standalone drug. Therefore, its safety and efficacy for human use are not yet fully determined.

Are there any known side effects of TB4-FRAG?

In preclinical animal studies, Ac-SDKP has generally shown good tolerability at therapeutic doses, with no severe systemic side effects commonly reported. As with any injectable substance, mild, localized irritation at the injection site is a theoretical possibility based on general pharmacological principles.

How is TB4-FRAG typically administered in research?

In research settings, particularly in animal models, TB4-FRAG is typically administered systemically via subcutaneous (under the skin) or intraperitoneal (into the abdominal cavity) injections.

Can TB4-FRAG be combined with other medications?

Preclinical research suggests that exogenous TB4-FRAG can provide additive or synergistic benefits when combined with agents like ACE inhibitors or ARBs, as these drugs influence the endogenous levels or related pathways of Ac-SDKP. However, any such combinations are purely investigational and not recommended outside of controlled research settings.

How does TB4-FRAG specifically modulate inflammation and fibrosis?

TB4-FRAG (Ac-SDKP) exerts its anti-inflammatory effects by inhibiting NF-κB and AP-1 signaling pathways, reducing pro-inflammatory cytokine production like TNF-α and IL-6. In fibrosis, Ac-SDKP interferes with angiotensin-converting enzyme (ACE) activity. As an ACE substrate, it reduces the availability of angiotensin II, a potent pro-fibrotic mediator, thereby preventing excessive collagen deposition and tissue scarring. This dual action makes TB4-FRAG a significant compound for research into conditions involving chronic inflammation and tissue remodeling, such as organ fibrosis. Studies investigate its potential to mitigate damage and promote recovery. Researchers should adhere to established protocols and consider the complex interplay of pathways, always consulting safety data sheets and ethical guidelines.

What are common dosage ranges and administration frequencies for TB4-FRAG in preclinical studies?

Preclinical studies on TB4-FRAG often report dosages ranging from 0.01 mg/kg to 10 mg/kg, typically administered via subcutaneous (SC) or intraperitoneal (IP) injection in rodent models. The specific dose depends on the animal model, target tissue, and desired outcome, aimed at achieving systemic availability to modulate pathways like ACE inhibition or NF-κB suppression. Administration frequency usually varies from once daily to three times a week, adjusted based on the peptide's half-life and the chronicity of the studied condition. For example, daily administration for several weeks is common in cardiac fibrosis models. Researchers should meticulously review literature for similar models and conduct pilot studies to establish effective and safe dosing, prioritizing animal welfare and seeking expert consultation.

Are there specific populations or conditions where TB4-FRAG research suggests caution?

While TB4-FRAG generally shows a favorable safety profile in preclinical studies, research suggests caution in specific contexts. Its interaction with the ACE pathway means concurrent use with ACE inhibitors or angiotensin receptor blockers could theoretically affect blood pressure or renal function, though not extensively studied. Given its role in modulating growth factors and inflammation, its use in models with rapidly proliferating cells or certain cancer types warrants careful evaluation. In research, careful consideration is needed when studying TB4-FRAG in models involving cardiovascular disease, renal impairment, or oncological conditions where existing treatments already target related pathways. Comprehensive toxicological assessments are vital to identify any potential off-target effects. Always consult appropriate research protocols and safety guidelines, and seek expert advice for specific population considerations.

How does TB4-FRAG differ from full-length Thymosin Beta 4 (TB4)?

TB4-FRAG (Ac-SDKP) is a naturally occurring tetrapeptide fragment derived from full-length Thymosin Beta 4 (TB4). While both share some biological activities, their primary mechanisms and potencies differ. TB4 is a larger protein involved in actin sequestration, cell migration, and broad tissue regeneration. Ac-SDKP, being a smaller peptide, primarily acts as an antifibrotic and anti-inflammatory agent, largely through its interaction with ACE and modulation of specific signaling pathways. The smaller size of TB4-FRAG can lead to distinct pharmacokinetic properties, potentially affecting bioavailability and half-life compared to the larger TB4 molecule. This often makes Ac-SDKP more stable. Researchers typically choose between them based on the specific biological effect they aim to study, with Ac-SDKP often preferred for targeted anti-fibrotic or anti-inflammatory research. Always ensure research is conducted under strict ethical guidelines and consult relevant scientific literature for comparative data.

How quickly might the effects of TB4-FRAG be observed in research models?

The onset of TB4-FRAG's effects varies significantly based on the condition, dosage, and measured endpoint. For acute inflammatory responses, modulatory effects on cytokine expression might be observed within hours to a few days. For complex processes like fibrosis reversal or tissue regeneration, sustained administration over several days to weeks is typically required before significant histological or functional changes become evident, due to the slower nature of cellular remodeling. For example, studies examining cardioprotective effects often involve daily administration for 1-4 weeks to observe reductions in fibrosis or improvements in cardiac function. For wound healing, improvements might be noted within days. Researchers must design experiments with appropriate timelines to capture desired effects. Always follow established research protocols and prioritize animal welfare, consulting experts for optimal experimental design.

PeptideKey Intelligence

TB-500 Thymosin Beta-4 Fragment 1-4 — Pricing & Supplier Data

TB-500 Thymosin Beta-4 Fragment 1-4 pricing, purity certificates, and supplier comparison. Verified COA data and independent lab testing from PeptideKey.

This product analysis is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.